Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kari Lenita Falck Moore

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Ejhaem|August 19, 2024
Incidence and prevention of skeletal-related events in multiple myeloma patients: A population-based real-world experienceMarie Røra, Margrete Skretting Solberg, Kari Lenita Falck Moore, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|April 21, 2026
High-dose melphalan and autologous haematopoietic stem cell transplantation in multiple myeloma in Norway, 2008-2020Jakob Nordberg Nørgaard, Kari Lenita Falck Moore, Tobias S Slørdahl, et al.
Haematologica|October 27, 2022
Improved survival in myeloma patients-a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and SwedenKari Lenita Falck Moore, Ingemar Turesson, Anna Genell, et al.
Haematologica|September 4, 2025
Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study GroupKari Lenita Falck Moore, Samundur Rognvaldsson, Agoston G Szabo, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Ejhaem|August 19, 2024
Incidence and prevention of skeletal-related events in multiple myeloma patients: A population-based real-world experienceMarie Røra, Margrete Skretting Solberg, Kari Lenita Falck Moore, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|April 21, 2026
High-dose melphalan and autologous haematopoietic stem cell transplantation in multiple myeloma in Norway, 2008-2020Jakob Nordberg Nørgaard, Kari Lenita Falck Moore, Tobias S Slørdahl, et al.
Haematologica|October 27, 2022
Improved survival in myeloma patients-a nationwide registry study of 4,647 patients ≥75 years treated in Denmark and SwedenKari Lenita Falck Moore, Ingemar Turesson, Anna Genell, et al.
Haematologica|September 4, 2025
Use of upfront autologous stem cell transplantation in myeloma patients aged >65 years: a population-based study by the Nordic Myeloma Study GroupKari Lenita Falck Moore, Samundur Rognvaldsson, Agoston G Szabo, et al.
Pageof 1